Karin Bryskhe, CEO of Colloidal Resource tells us how they can help Pharma Companies save time and money in the preclinical phase




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Karin Bryskhe, CEO of Colloidal Resource tells us how they can help Pharma Companies save time and money in the preclinical phase
Released on: October 14, 2011. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Karin Bryskhe, CEO of Colloidal Resource
Colloidal Resource: Expertise in Colloidal science
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston, in September 2011. On this show I have Karin Bryskhe , who is the CEO of a company called Colloidal Resource which is based in Lund in Sweden, welcome to the show.
Karin Bryskhe:
Thank you very much.
Fintan Walton:
Karin, Colloidal Resource as I said is based in Lund it has many operations, but one of the its operations as a company called CR Competence which deals in the area of science of colloidal science and research and we are here to talk about that CR Competence, but first of all my first question to you is what does CR Competence do?
Karin Bryskhe:
Yes, we are experts in colloidal science and colloidal science explains the interactions and structures in for example emulsions, dispersions, solutions and else these systems can typically be pharmaceutical formulations like drug delivery vehicles, and liposomes and even gel suspension that could be used for topical formulations.
Fintan Walton:
Okay, so how did you get into this particular field is that something that your own background is and how did you develop your expertise in Colloidal science?
Karin Bryskhe:
Yes all of us in the company have a PhD in Physical Chemistry, so I mean that we have the fundamental knowledge within this area, but the original the company was that we realized actually during our education we worked with a lot of industry in our PhD projects and realized that this colloidal chemistry actually fits in on a lot of different levels and different industries. I got frequently asked by larger companies already during my PhD for example Procter & Gamble on helping them solving these structural issues in their formulations.
The benefits of colloidal science for pharma companies
Fintan Walton:
Okay, so therefore you are obviously a specialist house if I can say that focused on colloidal science and colloidal chemistry now you've talked about its potential application or its actual application in pharmaceuticals you've also mentioned Procter & Gamble, can you tell us little bit more about for an example the type of research that you are doing on behalf of Procter & Gamble?
Karin Bryskhe:
Yes we are working with them closely and then have been done actually for many, many years. What we do for them is to help them to understand and characterize their formulation in the consumer product area, it could be formulations of for example hair care products and shampoos, but these formulations are the technologies used there, we have learned during these years are very could be used also in the pharmaceutical industry, so these synergies that you actually can get for working from different kind of industries has been very, very beneficial for higher clients in both industry.
Fintan Walton:
Okay, so what advantage can you bring to a pharmaceutical company with this science that you've got?
Karin Bryskhe:
We are totally convinced that by understanding these interactions in these dispersions and emulsions in drug delivery system on a detail level you actually save a lot of time and money in the preclinical phase and during these years we have shown that in a several projects that we have shortened the way to actually get really stable designed formulations for our clients.
Applications of colloidal science for formulations
Fintan Walton:
So just to, to get a better feeling for this obviously colloidal science as you mentioned that right at the very beginning in this interview how it is what that science is, so the typical type of application would be to in the formulation of drugs specifically?
Karin Bryskhe:
Yes, I can give you some examples I mean the typically is was I mentioned that the formulation how to design a stable formulation and also to understand how this formulation can be processed and so you get as a stable process of your product, another typical way to use to colloidal science in a very efficient way is to do we get a lot of questions from our clients in pharma of investigating the mode of action and to make sure that the mode of action of the component, compound is kept in the formulations, so we can develop matter to actually show that the mode of action of their compounds is kept in this particular formulation.
Fintan Walton:
Okay, so for companies out there who may have a problem let's say with the formulation they could come to you and look at see whether there is a colloidal science angle to that particular formulation problem I suppose, is it?
Karin Bryskhe:
Yes, definitely if you have a problem and the problems I mean what we've learned during these years often comes up when you come to up scaling may be you get some phase separation or your formulation doesn't behave as it did in the laboratory, but also of course what we prefer actually I would say, yes that may be they come to us before they come into these problems, of course we are happy to help on to that problems, but if they from the beginning starts to think about the colloidal perspective of this formulations you can avoid to get the problems.
Partnership strategy
Fintan Walton:
Right, so and at the moment you are where are you in your collaborations are you in negotiations with the particular companies at the moment in terms of use of that of your science and how far stretched into the pharmaceutical and life sciences businesses are you, you mentioned Procter & Gamble what are the types of companies are you looking at?
Karin Bryskhe:
Yes, Procter & Gamble like I mentioned, but of course we are working most of our clients I would say that we work with today and especially within pharma we are of course not allowed to talk about so but we have we are working with several pharma companies today and we just finalized one project and that was actually to verify that the idea they had about their mode of action was what they thought and to show them that these mode of action was kept in the formulation that they wanted to use. And another project that we just did for a pharmaceutical company was that they wanted to explore and investigate if there was a infringement of their patent, we can actually experimentally show and help them with their case to explore if they have any patent infringement and we have done that a couple of times because we have an unique possibility to use the instrumentation (indiscernable) on the university which make this possible for us to do a lot of experimental work to actually verify these, I mean it could be crucial for a pharmaceutical company if somebody infringe their patent.
Business model
Fintan Walton:
Right, and just finally then in terms of CR Competence itself you know where do you want to take that business? What's is it a business where you will ultimately just be purely a service based company or are you going to try and develop your own products?
Karin Bryskhe:
I will say we like being a service company, but what has happened and what we would like to go for now is that the latest project we have had with pharma and also personal care companies is like we do this joint development of for example of formulation and the business model is that we do these on a project basis like a not straight forward model but before we of course negotiate any upcoming IP, so in several other projects there actually the result has been new IP that we then could together with these pharmaceutical companies or in sometimes we have negotiated before of course that may be the IP will actually belong to the clients, but then of course I mean the deal looks in a different way.
Fintan Walton:
Right, so you are open to the concept of developing IP either jointly or wholly on by the sort of client?
Karin Bryskhe:
Yes and our thoughts for the future is actually that I think you get a better value for your money if we actually get larger projects and the possibility to develop these IP's, so I think we are going for more like research and development projects where we actually really explore new ways to measure things or new ways to deliver drugs and new drug delivery systems.
Fintan Walton:
Okay. Well Karin Bryskhe, thank you very much indeed for coming on the show.
Karin Bryskhe:
Thank you very much.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Karin Bryskhe
CEO
Karin Bryskhe presently serves as CEO of Colloidal Resource.Karin Bryskhe has been an entrepreneur since she ended her "around the world trip" in 1993. Now she has the position as CEO in two companies. In 2005 she founded her third company, Colloidal Resource a consultant business based at the chemical centre in Lund. In 2008 she won the Innovation Prize together with co-workers for an innovative way to use MR scanners without contrast fluids. For the same innovation she won the Venture cup business plan competition which has resulted in the resent founded company CR development. Karin Bryskhe graduated from Lund University and has a PhD in Physical Chemistry. Her thesis Formation of Block Copolymer and Surfactant Vesicles was founded on theoretical work as well as extensive laboratory work including techniques such as dynamic light scattering, NMR diffusion and cryo-transmission electron microscopy. She has a number of scientific publications and was recently nominated for the female entrepreneur award in Sweden.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Colloidal Resource
Colloidal Resource began in late summer 2005. Karin Bryskhe and Anna Stenstam was then recently qualified from the Division of Physical Chemistry 1 at Lund University, a department with the best reputation, both nationally and internationally. During the years of chemistry center, they had had experience of working with the latest technology in both traditional chemistry and in recent years the high-profile nano-chemistry. It was clear to both of them to the basis of chemistry are solutions to many problems as responsible for not only research but particularly product development is facing. Moreover, with a good plan is often only a few confirmatory tests and in academia are several tools that may be more useful. The possibility that the good relations with Lund University to work with the research community as a base - for companies with real product was the founding Colloidal Resource and the two subsidiaries. CR Development was born from the same environment - the actual presence of the chemical center. Together with Professor Daniel Topgaard, former graduate student colleague of Anna and Karin applied for patents on the technology, Daniel worked with. The possibility of Daniel's technology, previously used in yeast cells, could differentiate the different types of cancer laid the foundation for OncoPulse and the first subsidiary.